Share

February 14, 2017; 88 (7) Clinical/Scientific NotesOpen Access

Effect of interferon-free therapy on cognition in HCV and HCV/HIV infection: A pilot study

Felix Kleefeld, Sophie Heller, Heiko Jessen, Patrick Ingiliz, Antje Kraft, Katrin Hahn
First published December 21, 2016, DOI: https://doi.org/10.1212/WNL.0000000000003575
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1200

Share

Article Information

vol. 88 no. 7 713-715
DOI: 
https://doi.org/10.1212/WNL.0000000000003575
PubMed: 
28003502
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received May 16, 2016
  • Accepted in final form November 22, 2016
  • First Published December 21, 2016.

Article Versions

Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Felix Kleefeld,
    2. Sophie Heller,
    3. Heiko Jessen, MD,
    4. Patrick Ingiliz, MD,
    5. Antje Kraft, PhD and
    6. Katrin Hahn, MD
  1. Felix Kleefeld,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Sophie Heller,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Heiko Jessen, MD,
    4. Scientific Advisory Boards:

    1. Gilead Sciences GmbH, Bioscientia-Institute f?r Medizinische Diagnostik GmbH, ViiV Healthcare GmbH

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Gilead Sciences GmbH, ViiV Healthcare GmbH, Abbvie Deutschland GmbH & Co.KG, Bristol-Myers Squib GmbH & Co.KGaA

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Bioscientia-Institute f?r Medizinische Diagnostik GmbH

    Speakers' Bureaus:

    1. Gilead Sciences GmbH, ViiV Healthcare GmbH, Abbvie Deutschland GmbH & Co.KG, Bristol-Myers Squib GmbH & Co.KGaA

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Patrick Ingiliz, MD,
    5. Scientific Advisory Boards:

    1. 1) Abbvie 2) Gilead 3) ViiV

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) Abbvie 2) Gilead 3) BMS 4) MSD 5)Janssen-Cilag

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Antje Kraft, PhD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Katrin Hahn, MD
    7. Scientific Advisory Boards:

    1. Katrin Hahn served as an advisor on a scientific advisory board (Ultragenyx-commercial entity).

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Katrin Hahn, - has received honoraria for speaking engagements as well as travel honoraria from commercial entities such as AbbVie, Astellas, CSL Behring, Gilead, Pfizer, ViiV.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From Universitätsmedizin Charité (F.K., S.H., A.K., K.H.); Praxis Jessen2+Kollegen Berlin (H.J.); and Medizinisches Infektiologiezentrum Berlin (P.I.), Germany.
  1. Correspondence to Dr. Hahn: Katrin.hahn{at}charite.de
View Full Text

Article usage

Article usage: December 2016 to April 2023

AbstractFullPdfSource
Dec 2016414031Highwire
Jan 20173211275Highwire
Feb 2017101745113Highwire
Mar 2017921649Highwire
Mar 20170178pmc
Apr 201737321Highwire
Apr 201711421pmc
May 201723415Highwire
May 201761211pmc
Jun 2017331434Highwire
Jun 2017189pmc
Jul 2017251910Highwire
Jul 201741214pmc
Aug 201725115Highwire
Aug 2017377pmc
Sep 20171647Highwire
Sep 201731211pmc
Oct 20177310Highwire
Oct 2017277pmc
Nov 20172655Highwire
Nov 201731311pmc
Dec 20178104Highwire
Jan 201812126Highwire
Feb 2018111911Highwire
Mar 20188168Highwire
Apr 201851313Highwire
Apr 2018156pmc
May 2018232218Highwire
Jun 2018164814Highwire
Jun 2018278pmc
Jul 201853212Highwire
Aug 20183279Highwire
Aug 2018089pmc
Sep 20185167Highwire
Oct 2018133211Highwire
Nov 201892216Highwire
Dec 20188165Highwire
Jan 20196326Highwire
Feb 20197263Highwire
Mar 20196355Highwire
Apr 201910383Highwire
May 201913238Highwire
Jun 20196345Highwire
Jul 201911288Highwire
Aug 201916377Highwire
Sep 201912365Highwire
Oct 201914356Highwire
Nov 2019275216Highwire
Dec 201912445Highwire
Jan 202020418Highwire
Feb 2020164412Highwire
Mar 2020164813Highwire
Apr 20200106Highwire
May 20203911Highwire
Jun 2020192Highwire
Jul 20200712Highwire
Aug 2020084Highwire
Sep 20204148Highwire
Oct 20200254Highwire
Nov 202031610Highwire
Dec 20205294Highwire
Jan 20210286Highwire
Feb 20211195Highwire
Mar 20214244Highwire
Apr 20215277Highwire
May 20211188Highwire
Jun 20212395Highwire
Jul 202132312Highwire
Aug 202164314Highwire
Sep 20211276Highwire
Oct 202101918Highwire
Nov 202141717Highwire
Dec 20210345Highwire
Jan 20222256Highwire
Feb 20223544Highwire
Mar 202233312Highwire
Apr 20223176Highwire
May 202212310Highwire
Jun 20222117Highwire
Jul 20223234Highwire
Aug 20220262Highwire
Sep 20221129Highwire
Oct 20221129Highwire
Nov 20221152Highwire
Dec 20221136Highwire
Jan 20230115Highwire
Feb 20230212Highwire
Mar 20230246Highwire
Apr 20230151Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles